BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Trifluridine/tipiracil

35 mg/m², orally

DRUG

Bevacizumab

5 mg/kg, intravenous route

Trial Locations (10)

Unknown

CHU Amiens, Amiens

Centre Hospitalier Universitaire -Besançon, Besançon

Centre François Baclesse, Caen

Centre Hospitalier Departemental Vendee - Site Des Oudairies, La Roche-sur-Yon

Centre Hospitaler Universitaire de Lille, Lille

Hôpital privé Jean MERMOZ, Lyon

CHU Saint-Antoine, Paris

Institut Saint Catherine, Paris

CHU de BORDEAUX Hôpital HAUT-LEVEQUE, Pessac

Institut de cancérologie Strasbourg Europe, Strasbourg

All Listed Sponsors
collaborator

Servier

INDUSTRY

lead

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER